Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Re Bi Xiao
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Re Bi Xiao (热痹消) is a traditional Chinese medicine product or formula used in the context of rheumatoid arthritis and related inflammatory joint conditions. It is associated with the treatment of syndromes such as "Dampness heat obstruction" (湿热痹阻, shi re bi zu) or "Dampness heat obstructing the collaterals" (湿热阻络, shi re zu luo), which are patterns recognized in traditional Chinese medicine for inflammatory joint diseases[1]. The specific ingredients and mechanism of action are not detailed in available English-language sources. In clinical practice, it may be used to reduce inflammation and pain associated with these syndromes.
- Brand names
- Re Bi Xiao
- Other names
- 热痹消Rebi Xiao
Beyond the preview
Go deeper on Re Bi Xiao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Re Bi Xiao.